Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Alto Neuroscience from “strong sell” to “sell,” though the broader analyst consensus remains “Moderate Buy,” with eight Buy ratings, one Hold, two Sell ratings, and a $36.62 consensus price target.
• Alto Neuroscience shares opened at $32.14, near their 12-month high of $33.67, while the company reported a quarterly loss of $0.65 per share—better than the expected $0.73 loss.
• Institutional interest has increased, with firms including Commodore Capital, Jennison Associates, Orbimed Advisors, and Northwestern Mutual expanding or initiating positions in the clinical-stage biotechnology company.

Alto Neuroscience (NYSE:ANRO - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday.

Other analysts have also recently issued reports about the stock. Wolfe Research initiated coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They issued an "outperform" rating on the stock. HC Wainwright reaffirmed a "buy" rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Chardan Capital reiterated a "buy" rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. BTIG Research lifted their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Alto Neuroscience has an average rating of "Moderate Buy" and a consensus target price of $36.62.

Alto Neuroscience Trading Down 0.5%

Shares of ANRO opened at $32.14 on Friday. The business's 50-day moving average price is $25.97 and its 200-day moving average price is $22.75. Alto Neuroscience has a twelve month low of $3.05 and a twelve month high of $33.67. The stock has a market cap of $1.13 billion, a PE ratio of -13.28 and a beta of 1.06. The company has a quick ratio of 20.52, a current ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. On average, equities analysts forecast that Alto Neuroscience will post -3.14 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in ANRO. Northwestern Mutual Wealth Management Co. lifted its stake in Alto Neuroscience by 14,567.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company's stock worth $3,786,000 after purchasing an additional 211,222 shares during the last quarter. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the 1st quarter valued at about $8,687,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Alto Neuroscience during the 1st quarter valued at about $538,000. Orbimed Advisors LLC raised its holdings in shares of Alto Neuroscience by 34.0% during the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company's stock valued at $3,765,000 after buying an additional 42,500 shares in the last quarter. Finally, Commodore Capital LP lifted its position in Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company's stock worth $61,217,000 after buying an additional 900,000 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source